2.50
Hdl Handle:
http://hdl.handle.net/2436/40232
Title:
Hypertension in rheumatoid arthritis
Authors:
Panoulas, Vasileios F.; Metsios, Giorgos S.; Pace, A.V.; John, H.; Treharne, G.J.; Banks, M.J.; Kitas, George D.
Abstract:
RA associates with an increased burden of cardiovascular disease, which is at least partially attributed to classical risk factors such as hypertension (HT) and dyslipidaemia. HT is highly prevalent, and seems to be under-diagnosed and under-treated among patients with RA. In this review, we discuss the mechanisms that may lead to increased blood pressure in such patients, paying particular attention to commonly used drugs for the treatment of RA. We also suggest screening strategies and management algorithms for HT, specific to the RA population, although it is clear that these need to be formally assessed in prospective randomized controlled trials designed specifically for the purpose, which, unfortunately, are currently lacking.
Citation:
Rheumatology, 47(9): 1286-1298
Publisher:
Oxford University Press
Journal:
Rheumatology
Issue Date:
2008
URI:
http://hdl.handle.net/2436/40232
DOI:
10.1093/rheumatology/ken159
PubMed ID:
18467370
Additional Links:
http://rheumatology.oxfordjournals.org/cgi/content/abstract/47/9/1286
Type:
Article
Language:
en
ISSN:
1462-0332
Appears in Collections:
Sport, Exercise and Health Research Group

Full metadata record

DC FieldValue Language
dc.contributor.authorPanoulas, Vasileios F.-
dc.contributor.authorMetsios, Giorgos S.-
dc.contributor.authorPace, A.V.-
dc.contributor.authorJohn, H.-
dc.contributor.authorTreharne, G.J.-
dc.contributor.authorBanks, M.J.-
dc.contributor.authorKitas, George D.-
dc.date.accessioned2008-11-04T11:25:36Z-
dc.date.available2008-11-04T11:25:36Z-
dc.date.issued2008-
dc.identifier.citationRheumatology, 47(9): 1286-1298en
dc.identifier.issn1462-0332-
dc.identifier.pmid18467370-
dc.identifier.doi10.1093/rheumatology/ken159-
dc.identifier.urihttp://hdl.handle.net/2436/40232-
dc.description.abstractRA associates with an increased burden of cardiovascular disease, which is at least partially attributed to classical risk factors such as hypertension (HT) and dyslipidaemia. HT is highly prevalent, and seems to be under-diagnosed and under-treated among patients with RA. In this review, we discuss the mechanisms that may lead to increased blood pressure in such patients, paying particular attention to commonly used drugs for the treatment of RA. We also suggest screening strategies and management algorithms for HT, specific to the RA population, although it is clear that these need to be formally assessed in prospective randomized controlled trials designed specifically for the purpose, which, unfortunately, are currently lacking.en
dc.language.isoenen
dc.publisherOxford University Pressen
dc.relation.urlhttp://rheumatology.oxfordjournals.org/cgi/content/abstract/47/9/1286en
dc.subjectCardiovascularen
dc.subjectSystematic reviewen
dc.subjectRheumatoid Arthritisen
dc.subjectPhysical inactivityen
dc.subjectMedicationen
dc.subjectNon-steroidal anti-inflammatory drugsen
dc.subjectRecommendationsen
dc.subject.meshAnti-Inflammatory Agents, Non-Steroidalen
dc.subject.meshAntihypertensive Agentsen
dc.subject.meshArthritis, Rheumatoiden
dc.subject.meshGlucocorticoidsen
dc.subject.meshHumansen
dc.subject.meshHypertensionen
dc.subject.meshInflammationen
dc.subject.meshMotor Activityen
dc.subject.meshRisk Factorsen
dc.titleHypertension in rheumatoid arthritisen
dc.typeArticleen
dc.identifier.journalRheumatologyen

Related articles on PubMed

All Items in WIRE are protected by copyright, with all rights reserved, unless otherwise indicated.